We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

204 hedge funds and large institutions have $4.08B invested in Apellis Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 75 increasing their positions, 57 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 21

50% more call options, than puts

Call options by funds: $126M | Put options by funds: $84.1M

46% more capital invested

Capital invested by funds: $2.8B → $4.08B (+$1.28B)

32% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 57

17% more funds holding

Funds holding: 175 → 204 (+29)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0.73% less ownership

Funds ownership: 80.92% → 80.19% (-0.73%)

Holders
204
Holders Change
+29
Holders Change %
+16.57%
% of All Funds
3.55%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
51
Increased
75
Reduced
57
Closed
21
Calls
$126M
Puts
$84.1M
Net Calls
+$42M
Net Calls Change
+$25.5M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$78.9M
2
OCA
Octagon Capital Advisors
New York
+$36.5M
3
PA
Perceptive Advisors
New York
+$34.1M
4
BBA
Baker Bros. Advisors
New York
+$30.9M
5
Macquarie Group
Macquarie Group
Australia
+$28M

Top Sellers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
-$84M
2
CAM
Cormorant Asset Management
Massachusetts
-$52.4M
3
FCM
Farallon Capital Management
California
-$32.3M
4
Goldman Sachs
Goldman Sachs
New York
-$22.2M
5
CLOS
Compagnie Lombard Odier SCmA
Switzerland
-$19.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
201
Silverarc Capital Management
Massachusetts
$443 +$362K +7,009 New
Nisa Investment Advisors
202
Nisa Investment Advisors
Missouri
$186 – – –
Point72 Asset Management
203
Point72 Asset Management
Connecticut
– -$10.7M -250,000 Closed
GTC
204
Ghost Tree Capital
New York
– -$9.65M -225,000 Closed
WP
205
Woodline Partners
California
– -$7.36M -171,419 Closed
Millennium Management
206
Millennium Management
New York
– -$8.18M -158,571 Closed
California Public Employees Retirement System
207
California Public Employees Retirement System
California
– -$5.25M -122,358 Closed
BCM
208
Burrage Capital Management
Massachusetts
– -$3.46M -80,727 Closed
MSL
209
Mackay Shields LLC
New York
– -$1.39M -32,400 Closed
ACM
210
AlphaCrest Capital Management
New York
– -$794K -18,500 Closed
DA
211
Duality Advisers
Florida
– -$652K -15,188 Closed
Los Angeles Capital Management
212
Los Angeles Capital Management
California
– -$584K -13,611 Closed
EP
213
Eversept Partners
New York
– -$554K -12,900 Closed
AG
214
Algert Global
California
– -$385K -8,979 Closed
EGM
215
Engineers Gate Manager
New York
– -$323K -7,530 Closed
QSS
216
Quantitative Systematic Strategies
Florida
– -$281K -6,543 Closed
Pacer Advisors
217
Pacer Advisors
Pennsylvania
– -$72K -1,669 Closed
1C
218
1623 Capital
Virginia
– -$71K -1,655 Closed
ED
219
Exane Derivatives
France
– -$68.2K -1,589 Closed
FC
220
FORA Capital
Florida
– -$59K -1,378 Closed
Lazard Asset Management
221
Lazard Asset Management
New York
– -$56K -1,324 Closed
SPIA
222
Steward Partners Investment Advisory
New York
– -$32.2K -750 Closed
SFS
223
Sowell Financial Services
Arkansas
– -$16K -350 Closed
IA
224
IFP Advisors
Florida
– +$52 +1 New
Rockefeller Capital Management
225
Rockefeller Capital Management
New York
– +$516 +10 New
5 6 7 8
9

APLS Hedge Fund Activity: Q2 2021 in Review

204 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2021, worth a combined $4.08B — up 46% from $2.8B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new APLS positions and 21 closed out — a net gain of 30 holders — while 75 added to existing stakes and 57 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $78.9M. The largest seller was HHLR Advisors, cutting an estimated $84M.

  • 204 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2021, up from 175 in Q1 2021.
  • Funds reported $4.08B of Apellis Pharmaceuticals stock for Q2 2021, up 46% quarter-over-quarter.
  • 51 funds opened new Apellis Pharmaceuticals positions in Q2 2021 and 21 closed out, a net change of +30 holders.
  • The largest Apellis Pharmaceuticals buyer in Q2 2021 was T. Rowe Price Associates, an estimated $78.9M added.
  • The largest Apellis Pharmaceuticals seller in Q2 2021 was HHLR Advisors, an estimated $84M sold.

Based on aggregated 13F filings for Q2 2021.